Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans

The central nervous system is known to have limited regenerative capacity. Not only does this halt the human body’s reparative processes after central nervous system lesions, but it also impedes the establishment of effective and safe therapeutic options for such patients. Despite the high prevalenc...

Full description

Bibliographic Details
Main Authors: Magdalini Tsintou, Kyriakos Dalamagkas, Nikos Makris
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Neural Regeneration Research
Subjects:
Online Access:http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=3;spage=425;epage=437;aulast=Tsintou
id doaj-fc3b34dbc5264634852f6d0fcdb17855
record_format Article
spelling doaj-fc3b34dbc5264634852f6d0fcdb178552020-11-25T03:19:24ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53742020-01-0115342543710.4103/1673-5374.266048Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humansMagdalini TsintouKyriakos DalamagkasNikos MakrisThe central nervous system is known to have limited regenerative capacity. Not only does this halt the human body’s reparative processes after central nervous system lesions, but it also impedes the establishment of effective and safe therapeutic options for such patients. Despite the high prevalence of stroke and spinal cord injury in the general population, these conditions remain incurable and place a heavy burden on patients’ families and on society more broadly. Neuroregeneration and neural engineering are diverse biomedical fields that attempt reparative treatments, utilizing stem cells-based strategies, biologically active molecules, nanotechnology, exosomes and highly tunable biodegradable systems (e.g., certain hydrogels). Although there are studies demonstrating promising preclinical results, safe clinical translation has not yet been accomplished. A key gap in clinical translation is the absence of an ideal animal or ex vivo model that can perfectly simulate the human microenvironment, and also correspond to all the complex pathophysiological and neuroanatomical factors that affect functional outcomes in humans after central nervous system injury. Such an ideal model does not currently exist, but it seems that the nonhuman primate model is uniquely qualified for this role, given its close resemblance to humans. This review considers some regenerative therapies for central nervous system repair that hold promise for future clinical translation. In addition, it attempts to uncover some of the main reasons why clinical translation might fail without the implementation of nonhuman primate models in the research pipeline.http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=3;spage=425;epage=437;aulast=Tsintouanimal models; central nervous system regeneration; clinical translation; exosomes; hydrogels; neural tissue engineering; nonhuman primates; spinal cord injury; stem cells; stroke
collection DOAJ
language English
format Article
sources DOAJ
author Magdalini Tsintou
Kyriakos Dalamagkas
Nikos Makris
spellingShingle Magdalini Tsintou
Kyriakos Dalamagkas
Nikos Makris
Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
Neural Regeneration Research
animal models; central nervous system regeneration; clinical translation; exosomes; hydrogels; neural tissue engineering; nonhuman primates; spinal cord injury; stem cells; stroke
author_facet Magdalini Tsintou
Kyriakos Dalamagkas
Nikos Makris
author_sort Magdalini Tsintou
title Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
title_short Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
title_full Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
title_fullStr Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
title_full_unstemmed Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
title_sort taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans
publisher Wolters Kluwer Medknow Publications
series Neural Regeneration Research
issn 1673-5374
publishDate 2020-01-01
description The central nervous system is known to have limited regenerative capacity. Not only does this halt the human body’s reparative processes after central nervous system lesions, but it also impedes the establishment of effective and safe therapeutic options for such patients. Despite the high prevalence of stroke and spinal cord injury in the general population, these conditions remain incurable and place a heavy burden on patients’ families and on society more broadly. Neuroregeneration and neural engineering are diverse biomedical fields that attempt reparative treatments, utilizing stem cells-based strategies, biologically active molecules, nanotechnology, exosomes and highly tunable biodegradable systems (e.g., certain hydrogels). Although there are studies demonstrating promising preclinical results, safe clinical translation has not yet been accomplished. A key gap in clinical translation is the absence of an ideal animal or ex vivo model that can perfectly simulate the human microenvironment, and also correspond to all the complex pathophysiological and neuroanatomical factors that affect functional outcomes in humans after central nervous system injury. Such an ideal model does not currently exist, but it seems that the nonhuman primate model is uniquely qualified for this role, given its close resemblance to humans. This review considers some regenerative therapies for central nervous system repair that hold promise for future clinical translation. In addition, it attempts to uncover some of the main reasons why clinical translation might fail without the implementation of nonhuman primate models in the research pipeline.
topic animal models; central nervous system regeneration; clinical translation; exosomes; hydrogels; neural tissue engineering; nonhuman primates; spinal cord injury; stem cells; stroke
url http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=3;spage=425;epage=437;aulast=Tsintou
work_keys_str_mv AT magdalinitsintou takingcentralnervoussystemregenerativetherapiestothecliniccuringrodentsversusnonhumanprimatesversushumans
AT kyriakosdalamagkas takingcentralnervoussystemregenerativetherapiestothecliniccuringrodentsversusnonhumanprimatesversushumans
AT nikosmakris takingcentralnervoussystemregenerativetherapiestothecliniccuringrodentsversusnonhumanprimatesversushumans
_version_ 1724622536505819136